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Abstract
Background: To monitor the impact of human papillomavirus types 16 and 18 vaccine on HPV infection dynamics in the
Netherlands, we started an ongoing study in sexually transmitted infection (STI) clinics in 2009. Here, we analyze baseline
type-specific HPV DNA and HPV-specific antibody positivity rates.
Methods: We enrolled 3569 men and women, 16–24 years of age, from 14 STI clinics, and estimated genital and anal HPV
DNA and antibody positivity rates of 7 main carcinogenic HPV types. Generalized estimating equations regression analyses
were applied to determine risk factors for, and associations between, type-specific HPV DNA and antibody positivity.
Results: Genital HPV DNA positivity rates were higher in women than in men; anal HPV DNA was especially high in men who
have sex with men (MSM). HPV antibody seropositivity rates were also highest in women and MSM. High-risk sexual
behavior was predictive of both HPV DNA and antibody positivity. Despite a strong correlation in serological profiles for
multiple HPV types, seropositivity was independently associated with homologous HPV DNA detection.
Conclusions: HPV DNA and antibody positivity rates are higher in women and MSM than in heterosexual men, but their
association is similar across gender. This suggests a site-specific natural course of infection.
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Introduction
Human papillomavirus (HPV) is a common sexually transmitted
virus known for its causal relation to cervical cancer. There are
more than 100 HPV genotypes, with more than 15 carcinogenic
types [1,2]. In many countries, HPV vaccination has been
introduced in sexually naı¨ve girls to prevent infections with
HPV-16/-18, which are most commonly found in cervical cancers.
It is not yet known what the impact of HPV vaccination will be on
HPV dynamics in partially vaccinated populations. Monitoring of
type-specific HPV prevalence in both vaccinated and nonvacci-
nated people is, therefore, of great importance.
HPV infection does not always induce an immune response that
results in HPV-specific antibodies (Ab) [3,4,5]. Even if women are
diagnosed with precancerous cervical lesions that test positive for
HPV DNA, they might still be negative for serum HPV Ab [6].
Whether HPV infection will lead to seroconversion depends on
several factors, such as specific HPV types, persistence of infection,
HPV DNA viral load, and site of infection [3,4,7,8,9,10,11]. In
contrast to natural infection, HPV vaccination induces an immune
response with high concentrations of HPV Ab, by far exceeding
the HPV Ab concentrations found in nonvaccinated populations
[12]. In addition, studies showed that vaccination against HPV-
16/-18 can result in cross-protection against phylogenetically
related genotypes [13,14]. Therefore, it is possible that vaccination
may not only result in a decline in HPV-16/-18 prevalence, but
also in a decline in phylogenetically related genotypes such as
HPV-31, -33, and -45. Conversely, unwanted effects like type
replacement, i.e., the potential for nonvaccine HPV types to
occupy the vacated ecologic niches, can occur as a result of the
elimination of HPV-16/-18 [15]. This hypothesis has neither been
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confirmed nor rejected by epidemiological studies. As a result of
reduced exposure to HPV-16/-18, an effect can also be expected
among nonvaccinated men and women [16,17,18,19].
The aim of our study was to describe HPV DNA and HPV-
specific Ab detection rates of women, men who have sex with
women only (MSW), and men who have sex with men (MSM), all
of whom were without benefit of HPV vaccination. Furthermore,
we explored associations between homologous and heterologous
pairs of HPV DNA and HPV Ab types. This description will serve
as a baseline measurement to which we can compare future
monitoring rounds on HPV dynamics within the Netherlands.
Materials and Methods
Ethics Statement
The medical ethics committee of the University of Utrecht, the
Netherlands, confirmed in writing that they waived the need for
separate ethical approval and the need for written consent. This
anonymous study used serum already collected for routine STI
consultation, therefore no additional invasive procedures were
needed. All eligible participants were informed about the purpose
of the study prior to the regular STI consultation and full
information was provided about the samples to be collected and
the additional questionnaire to be administered. Only participants
who consented verbally with all conditions were included in the
study.
Study Population and Design
In 2009, the bivalent HPV vaccine was introduced in the
Netherlands among 12- to 16-year-old girls. To monitor the effects
of HPV-16/-18 vaccination on type-specific HPV dynamics in a
young highly sexually active population, the PASSYON (PApil-
lomavirus Surveillance among STI clinic YOungsters in the
Netherlands) study was set up [20]. This biennial cross-sectional
study includes 16- to 24-year-old male and female attendees of the
sexually transmitted infection (STI) clinic. In 2009 and 2011, the
first two rounds of this study took place in 14 STI clinics
throughout the Netherlands; 10 STI clinics participated in both
rounds.
A genital self-sample (vaginal or penile) of all participants was
requested (sampling technique is described elsewhere [20]). In
addition, MSM were requested for an anal sample as well.
Procedures were similar in both rounds, however, in 2011, females
and MSW also were invited to submit an anal sample. In addition,
participation included: the use of serum already collected during
routine consultation or collection of an extra blood sample if
routine serum was not available; filling out a questionnaire; and
permission to link the anonymous standardized data collected
during the intake of the routine consultation with STI test results
(e.g., Chlamydia trachomatis, Neisseria gonorrhoea, syphilis, HIV). The
questionnaire covered sexual risk factors such as condom use,
number of sex partners, and history of STI. Demographic data
were also collected. Ethnicity was not recorded, but we asked the
participants which population they belonged to, regardless of
country of birth, and used their responses as proxies.
HPV DNA detection
All swabs were suspended in 1 ml universal transport medium
buffer and stored at 220uC until processing. After thawing, swabs
were vortexed and 200 mL of the sample was spiked with phocine
herpes virus-1. DNA was subsequently extracted using the
MagnaPure platform (Total Nucleic Acid Isolation Kit, Roche)
and eluted in 100 mL elution buffer. HPV-DNA was amplified
using the SPF10 primer set according to the manufacturer’s
instructions (DDL Diagnostic Laboratory, the Netherlands [21]).
HPV-specific amplicons were detected using the DNA enzyme-
linked immunoassay (HPV-DEIA, DDL Diagnostic Laboratory,
the Netherlands). Amplicons of HPV-positive samples were
subsequently analyzed in Line probe assay (HPV-LiPA, DDL
Diagnostic Laboratory, the Netherlands). In this report, only the
seven carcinogenic HPV types, which can also be detected in the
Ab detection assay, are reported (i.e., HPV-16, -18, -31, -33, -45, -
52, -58). Only persons positive for one of the seven HPV-types are
reported as being HPV positive.
Serum antibody detection
Serum samples were stored at 280uC until analysis. HPV-
specific serum antibodies against L1 virus-like particles (VLPs) for
serotypes -16, -18, -31, -33, -45, -52 and -58 were assessed using a
VLP-based multiplex immunoassay in which the VLPs were
coupled to a set of seven distinct fluorescent microspheres. VLPs
were kindly donated by GSK. Most samples were analysed with a
1/100 or 1/200 dilution, some in 1/2000 dilution. Serum samples
were assumed to be antibody seropositive at cut-offs determined
previously with this assay: 9, 13, 27, 11, 19, 14, 31 Luminex
Units/millilitre (LU/ml) for HPV-16, -18, -31, -33, -45, -52, -58,
respectively. The serological measurements and control steps have
been described in more detail elsewhere [22].
Statistical Analyses
Since no significant differences were observed in HPV DNA or
Ab positivity rates between the first two rounds (2009 and 2011),
we chose to combine these rounds in this study to gain more
power. We included only HIV-negative persons having a
urogenital DNA sample as well as a serum sample. Women who
reported HPV vaccination were excluded in these baseline
analyses. We did not exclude men who reported to be HPV
vaccinated (n = 17), since Ab concentrations of HPV-16/-18 were
not significantly different from those of persons who reported not
to be HPV vaccinated, and since men are not (yet) vaccinated in
the Netherlands for HPV, it was unlikely that they actually had
been vaccinated. Type-specific positivity rates for the seven
detectable HPV DNA and HPV Ab types were estimated,
stratified by women, MSW, and MSM. Positivity rates were
estimated by dividing the number of type-specific HPV DNA
positives by the total number tested, with 95% confidence intervals
(CI) based on Wilson’s score method. The Student’s t-test was used
to compare positivity rates. When the number testing positive was
below five the Fisher’s exact test was used.
Generalized estimating equations (GEE) analyses were per-
formed to assess independent risk factors associated with the
presence of HPV DNA, and separate analyses were performed to
asses independent risk factors associated with HPV Ab seropos-
itivity. GEE models are marginal and take into account multiple
measurements, making them highly suitable for estimating
population-averaged risks associated with repeated measures
[23]. GEE models estimate conditional log odds ratios (bx)
between an independent risk factor (x) and a multivariate outcome
variable, while assuming a particular correlation structure between
the repeated measures, in this case multiple HPV types [24]. In
assessing independent risk factors for the presence of HPV DNA
and for HPV Ab seropositivity, we used an ‘exchangeable
correlation’ structure with a common odds ratio alpha, which is
appropriate when the association between pairs of HPV types can
be assumed to be constant. Analyses were stratified by gender (i.e.,
women, MSW, MSM), since univariable analyses showed that all
three outcome variables (genital HPV DNA, anal HPV DNA, and
HPV Ab) differed significantly between women, MSW, and MSM.
HPV DNA and Antibody Positivity
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Table 1. Demographics and characteristics of the study population: women, MSW, and MSM.
Female MSW MSM Total
N=2233 N=922 N=173 N=3328
n (%) n (%) n (%) n (%)
Year of participation
2009 1069 (47.9) 414 (44.9) 68 (39.3) 1551 (46.6)
2011 1164 (52.1) 508 (55.1) 105 (60.7) 1777 (53.4)
Age
16–18 years 249 (11.2) 61 (6.6) 17 (9.8) 327 (9.8)
19–21 years 974 (43.6) 351 (38.1) 71 (41.0) 1396 (41.9)
22–24 years 1010 (45.2) 510 (55.3) 85 (49.1) 1605 (48.2)
Ethnicity
Dutch 1925 (86.2) 741 (80.4) 137 (79.2) 2803 (84.2)
Non-Dutch 308 (13.8) 181 (19.6) 36 (20.8) 525 (15.8)
Educational level*
Low 512 (22.9) 281 (30.5) 57 (32.9) 850 (25.5)
High 1655 (74.1) 605 (65.6) 109 (63.0) 2369 (71.2)
Unknown 66 (3.0) 36 (3.9) 7 (4.0) 109 (3.3)
Years sexual active
0–2 years 411 (18.4) 97 (10.5) 32 (18.5) 540 (16.2)
3–4 years 576 (25.8) 224 (24.3) 47 (27.2) 847 (25.5)
$5 years 1179 (52.8) 562 (61.0) 87 (50.3) 1828 (54.9)
Unknown 67 (3.0) 39 (4.2) 7 (4.0) 113 (3.4)
Steady or casual sex partner
No partner 1009 (45.2) 348 (37.7) 71 (41.0) 1428 (42.9)
Steady partner 878 (39.3) 409 (44.4) 61 (35.3) 1348 (40.5)
Casual partner 237 (10.6) 99 (10.7) 21 (12.1) 357 (10.7)
Steady and casual partner 52 (2.3) 28 (3.0) 14 (8.1) 94 (2.8)
Unknown 57 (2.6) 38 (4.1) 6 (3.5) 101 (3.0)
Condom use steady partner, past 6 months
Inconsistent condom use 726 (32.5) 337 (36.6) 45 (26.0) 1108 (33.3)
Consistent condom use 201 (9.0) 98 (10.6) 30 (17.3) 329 (9.9)
No steady partner 1251 (56.0) 449 (48.7) 92 (53.2) 1792 (53.8)
Unknown 55 (2.5) 38 (4.1) 6 (3.5) 99 (3.0)
Condom use casual partner, past 6 months
Inconsistent condom use 728 (32.6) 349 (37.9) 31 (17.9) 1108 (33.3)
Consistent condom use 834 (37.3) 317 (34.4) 117 (67.6) 1268 (38.1)
No casual partner 620 (27.8) 220 (23.9) 19 (11.0) 859 (25.8)
Unknown 51 (2.3) 36 (3.9) 6 (3.5) 93 (2.8)
Number of sex partners, lifetime
1–4 partners 762 (34.1) 187 (20.3) 29 (16.8) 978 (29.4)
5–9 partners 804 (36.0) 249 (27.0) 29 (16.8) 1082 (32.5)
$10 partners 612 (27.4) 442 (47.9) 113 (65.3) 1167 (35.1)
Unknown 55 (2.5) 44 (4.8) 2 (1.2) 101 (3.0)
Number of sex partners, past 6 months
0–1 partners 806 (36.1) 232 (25.2) 28 (16.2) 1066 (32.0)
2–3 partners 1048 (46.9) 379 (41.1) 62 (35.8) 1489 (44.7)
$4 partners 375 (16.8) 310 (33.6) 83 (48.0) 768 (23.1)
Unknown 4 (0.2) 1 (0.1) 0 (0.0) 5 (0.2)
Passive anal intercourse, past 6 months
No 1938 (86.8) 917 (99.5) 44 (25.4) 2899 (87.1)
HPV DNA and Antibody Positivity
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Multivariable analyses were performed by including the following
variables into a GEE model: age, ethnicity, years sexually active,
number of lifetime sex partners, number of sex partners in the last
six months, condom use in the last six months with a steady
partner, condom use in the last six months with a casual partner, a
chlamydia or gonorrhea infection in the past, a current urogenital
chlamydia infection, a current anogenital chlamydia or gonorrhea
infection, passive anal sex in the past six months, and the seven
different HPV genotypes. Subsequently, all nonsignificant
(p$0.05) variables were removed by backward selection.
GEE models were also used to estimate possible type-specific
associations between the presence of HPV DNA and HPV Ab.
These analyses were also stratified by gender, but could not be
performed for MSM because of the small group size. For these
analyses, we used a saturated model for the independent risk
factors and started with a fully parameterized model for the pair-
wise log odds ratios between all 14 genital HPV DNA and HPV
Ab outcome variables. The starting log odds ratio model was
composed of 14613/2= 91 linear parameter combinations, one
for each unique binary pair of type-specific DNA and/or Ab of the
seven HPV types. All nonsignificant parameters were subsequently
deleted from the model using Bonferroni-corrected p values based
on Wald tests, and this procedure was repeated until all remaining
parameters were significant. Final estimates were obtained after
orthonormal transformation of the log odds ratio estimation
matrix. In modelling the association between pairs of responses,
we made use of the alternating logistic regression algorithm of the
SAS GENMOD procedure [25].
Table 1. Cont.
Female MSW MSM Total
N=2233 N=922 N=173 N=3328
n (%) n (%) n (%) n (%)
Yes 253 (11.3) 5 (0.5) 129 (74.6) 387 (11.6)
Unknown 42 (1.9) 0 (0.0) 0 (0.0) 42 (1.3)
*High educational level includes university of science and university of professional education, low educational level includes all other forms of education.
MSM=men who have sex with men; MSW=men who have sex with women only.
doi:10.1371/journal.pone.0060696.t001
Table 2. Past and current (ano)genital chlamydia and gonorrhea infections: women, MSW, and MSM.
Female MSW MSM Total
N=2233 N=922 N=173 N=3328
n (%) n (%) n (%) n (%)
Chlamydia or gonorrhea ever
No 1424 (63.8) 568 (61.6) 107 (61.8) 2099 (63.1)
Yes 420 (18.8) 127 (13.8) 41 (23.7) 588 (17.7)
Never tested before 326 (14.6) 190 (20.6) 16 (9.2) 532 (16.0)
Unknown 63 (2.8) 37 (4.0) 9 (5.2) 109 (3.3)
Current urogenital chlamydia infection
No 1917 (85.8) 792 (85.9) 164 (94.8) 2873 (86.3)
Yes 307 (13.7) 122 (13.2) 8 (4.6) 437 (13.1)
Unknown/not tested 9 (0.4) 8 (0.9) 1 (0.6) 18 (0.5)
Current urogenital gonorrhea infection
No 2194 (98.3) 897 (97.3) 164 (94.8) 3255 (97.8)
Yes 32 (1.4) 17 (1.8) 7 (4.0) 56 (1.7)
Unknown/not tested 7 (0.3) 8 (0.9) 2 (1.2) 17 (0.5)
Current anal chlamydia infection
No 96 (4.3) 5 (0.5) 121 (69.9) 222 (6.7)
Yes 24 (1.1) 0 (0.0) 16 (9.2) 40 (1.2)
Unknown/not tested 2113 (94.6) 917 (99.5) 36 (20.8) 3066 (92.1)
Current anal gonorrhea infection
No 340 (15.2) 8 (0.9) 141 (81.5) 489 (14.7)
Yes 7 (0.3) 0 (0.0) 13 (7.5) 20 (0.6)
Unknown/not tested 1886 (84.5) 914 (99.1) 19 (11.0) 2819 (84.7)
MSM=men who have sex with men; MSW=men who have sex with women only.
doi:10.1371/journal.pone.0060696.t002
HPV DNA and Antibody Positivity
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Results
Characteristics study population
In 2009 and 2011, 1637 and 1932 participants, respectively,
were tested for a genital HPV infection. Of these 3569
participants, 3439 (96%) were also tested for HPV Ab. After
exclusion of 6 HIV-positive persons and 105 self-reported HPV-
vaccinated women, a study population of 3328 participants
remained, of whom two-thirds were females (n = 2233). A
subgroup of 118 (5%) women, 56 (6%) MSW, and 124 (72%)
MSM also had a test result for anal HPV DNA infection.
Characteristics stratified for women, MSW, and MSM are given
in Table 1. The median age of the 3328 participants was 21 years
(IQR: 20–23 years). Of all men, 16% (n= 173) reported having sex
with men. Sexual behavioral factors showed a median age of first
intercourse of 16 years (IQR: 15–17 years) and a median number
of lifetime partners of 7 (IQR: 4–12) (6, 9, and 12 lifetime partners
for women, MSW, and MSM, respectively). The percentage of
persons with a current or past anogenital chlamydia or gonorrhoea
infection is given in Table 2. Among women and MSW, 14% had
a current urogenital chlamydia and 2% had a current gonorrhea
infection. For MSM this was 5% and 4%, respectively. A current
anal chlamydia and/or gonorrhea infection was reported for 1%
of women and 14% of MSM. No anal infections were seen in
MSW.
HPV DNA positivity and HPV-specific antibody
seropositivity
Women had the highest genital HPV DNA positivity rate (45%)
with the highest type-specific rate for HPV-16 (17% of all women).
Among men, MSM had lower positivity rates for genital (penile)
DNA than MSW, 16% versus 26%, respectively. Although low
genital HPV DNA positivity rates were seen in MSM, anal HPV
DNA positivity rates were high. Within the subgroups that also
provided anal samples (124 MSM, 118 women, and 56 MSW),
similar anal HPV DNA positivity rates were seen in MSM (33%)
and women (32%), whereas anal HPV DNA positivity was rare in
MSW (4%) (Figure 1). HPV seropositivity was highest in women
(49%), followed by MSM (34%) and MSW (19%).
Comparing HPV DNA positivity and HPV Ab seropositivity
rates by gender, the main differences were the lower positivity
rates for HPV Ab -16, -18, -31, and -52 compared to homologous
HPV DNA positivity rates in MSW (Figure 2a–c). Women and
MSM, however, had generally higher positivity rates for HPV Ab
in comparison to homologous HPV DNA positivity rates. When
comparing anal and genital infections in MSM, the anal HPV
DNA positivity rates were higher than the genital HPV DNA
positivity rates, although not significant (p = 0.25) (Figure 2c–d).
Subsequently, the percentage of simultaneous detection of HPV
DNA and homologous HPV Ab increased. The difference
between anal HPV DNA positivity and HPV Ab seropositivity
in MSM was similar to the genital rates observed in women. When
observing women and MSM with both a genital as well as an anal
sample, differences were seen for HPV Ab seropositivity among
those infected with HPV DNA at one anatomical site only.
Although numbers were small, women tended to be more often
HPV Ab seropositive when only a genital HPV DNA infection was
present compared to MSM (45% versus 18%, respectively
(p = 0.16)). Whereas, HPV Ab seropositivity rates when only an
anal HPV DNA infection was present were quite similar between
women and MSM (29% versus 21%, respectively (p = 0.71)).
Simultaneous detection of type-specific HPV DNA and
homologous HPV Ab genotype was most frequent for genotype
16 among all genders and sites. From Figure 2a–b, the odds ratio
Figure 1. Positivity rate for genital and anal DNA detection in women, MSW and MSM. Black gives the positivity rate for persons with a
HPV DNA detection only at the genitals, dark grey gives the positivity rate for persons with an HPV DNA infection genital as well as anal, and light
grey are the positivity rates when persons are only detected with HPV DNA anally. The figures includes women (N= 118), MSW (N=56) and MSM
(N= 124) of whom a genital and an anal sample were available. MSW= men who have sex with women only; MSM=men who have sex with men.
doi:10.1371/journal.pone.0060696.g001
HPV DNA and Antibody Positivity
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for HPV-16 Ab seropositivity together with HPV-16 DNA
positivity is directly estimated at 2.9 for women and at 3.3 for
MSW. However, given the presence of HPV-16 DNA, the
probability of testing positive for HPV-16 Ab is much higher for
women than for MSW, 41% versus 11%, respectively (p,0.01).
Determinants of HPV DNA positivity and HPV-specific
antibody seropositivity
Multivariable analyses resulted in different risk factors for
genital HPV DNA positivity, anal HPV DNA positivity, and HPV
Ab seropositivity. Most noticeable was the significant association of
ethnicity with HPV Ab seropositivity for women as well as MSM,
whereas ethnicity was not significantly associated with HPV DNA
positivity. Persons who reported they were non-Dutch were more
likely to be HPV Ab seropositive. Furthermore, in women the site
of the current chlamydia infection corresponded with the site of
the associated HPV DNA positivity: a genital chlamydia infection
was associated with genital HPV DNA infection and an anal
chlamydia infection with an anal HPV DNA infection. In MSM,
reporting passive anal sex in the past six months was associated
with HPV Ab seropositivity. All significant risk factors resulting
from the multivariable GEE analysis are shown in Table 3, 4 and
5.
Association between genital HPV DNA and HPV-specific
antibody genotypes
The log odds ratio model for genital HPV DNA positivity and
HPV Ab seropositivity could be reduced from a total of 91
parameters to as few as 7 independent parameters in women.
Table 6 shows the resulting estimates of the common odds ratios
for any pair of the following: (1) homologous HPV DNA and HPV
Ab genotypes; (2) HPV DNA genotypes; (3) HPV Ab genotypes;
and (4) heterologous DNA and Ab genotypes. In addition to these
associations, we found significantly increased odds ratios for DNA
and Ab of HPV-58; DNA of HPV-31 and HPV-33; and Ab
detection for a subset of genotypes (i.e., HPV-33, -45, -52, -58).
For example, seropositivity for HPV-33 Ab in combination with
HPV-45 Ab is a frequently occurring test result, as well as
seropositivity for HPV-33 Ab with HPV-52 Ab. For MSW, the
number of independent parameters that could be estimated was
smaller than for women, which is in line with the smaller sample
size and lower positivity rate in MSW as compared to women.
Associations were similar between the sexes (Table 6), except that
a much stronger association was observed between pairs of HPV
Ab genotypes in MSW compared with women.
The results of the log odds ratio model provided a justification
for the assumption of an ‘exchangeable correlation’ structure in
Figure 2. Genital (and anal) HPV DNA and HPV-specific antibody seropositivity in women, MSW, and MSM. Figure 2a–c gives the
genital HPV DNA (light grey), HPV-specific antibody seropositivity (dark grey), as well as the percentage of persons detected with genital HPV DNA as
well as HPV antibodies (black) with 95% confidence intervals in women (N= 2233), MSW (N= 922), and MSM (N=173) per HPV genotype. Figure 2d
gives the anal HPV DNA (light grey), HPV-specific antibody seropositivity (dark grey) as well as the percentage of persons detected with anal HPV DNA
as well as HPV antibodies (black) with 95% confidence intervals in MSM (N= 124). Ab= antibody; MSM=men who have sex with men; MSW=men
who have sex with women only.
doi:10.1371/journal.pone.0060696.g002
HPV DNA and Antibody Positivity
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assessing independent risk factors for the presence of HPV DNA
and for HPV Ab seropositivity. The associations between HPV
DNA genotypes or between HPV Ab genotypes estimated by the
log odds ratio model corresponded well with the alphas estimated
in the multivariable GEE analyses (Table 3, 4 and 5). Note that the
common odds ratios estimated by assuming an exchangeable
Table 3. Adjusted odds ratio and 95% confidence interval for the detection of genital and anal HPV DNA and HPV antibodies
using multilevel analyses (generalized estimating equations [GEE)]) in women.
Genital HPV DNA Anal HPV DNA HPV antibodies
AOR (95% CI) AOR (95% CI) AOR (95% CI)
Ethnicity
Dutch NS NS Reference
Non-Dutch 1.46 (1.19–1.78)
Years sexual active
0–2 years NS NS Reference
3–4 years 0.95 (0.73–1.22)
$5 years 1.20 (0.95–1.51)
Number of sex partners, lifetime
1–4 partners Reference Reference Reference
5–9 partners 1.37 (1.15–1.62) 0.31 (0.10–0.93) 1.40 (1.15–1.70)
$10 partners 2.02 (1.70–2.40) 0.94 (0.32–2.76) 2.23 (1.82–2.74)
Condom use steady partner, past 6 months
Inconsistent condom use NS NS Reference
Consistent condom use 0.79 (0.59–1.04)
No steady partner 0.82 (0.70–0.96)
Condom use casual partner, past 6 months
Inconsistent condom use Reference NS NS
Consistent condom use 0.94 (0.82–1.08)
No casual partner 0.66 (0.56–0.79)
History of chlamydia or gonorrhea
No Reference Reference Reference
Yes 1.29 (1.10–1.51) 4.52 (1.46–14.02) 1.83 (1.53–2.19)
Never tested before 1.08 (0.90–1.30) 1.32 (0.52–3.39) 0.80 (0.63–1.03)
Current urogenital chlamydia infection
No Reference NS NS
Yes 1.26 (1.06–1.50)
Current anal chlamydia/gonorrhea infection
No Reference Reference Reference
Yes 0.50 (0.28–0.91) 3.45 (1.01–11.73) 1.33 (0.76–2.36)
Not tested 0.77 (0.66–0.91) 0.52 (0.25–1.10) 0.65 (0.54–0.79)
HPV genotype
HPV16 Reference Reference Reference
HPV18 0.49 (0.41–0.59) 0.54 (0.21–1.42) 0.59 (0.51–0.68)
HPV31 0.65 (0.55–0.77) 0.81 (0.37–1.80) 0.38 (0.32–0.45)
HPV33 0.24 (0.19–0.30) 0.21 (0.06–0.77) 0.63 (0.55–0.72)
HPV45 0.15 (0.11–0.19) 0.14 (0.03–0.60) 0.66 (0.58–0.76)
HPV52 0.82 (0.70–0.97) 1.44 (0.69–3.03) 0.54 (0.47–0.62)
HPV58 0.17 (0.13–0.22) 0.22 (0.05–0.86) 0.40 (0.34–0.46)
Odds of having one HPV genotype when having another HPV genotype within an individual (Alpha)
1.54 (1.35–1.76) 1.81 (1.01–3.23) 4.34 (3.79–4.98)
The following variables were included into the crude GEE model: age, ethnicity, years sexually active, number of lifetime sex partners, number of sex partners in the last
six months, condom use in the last six months with a steady partner, condom use in the last six months with a casual partner, a chlamydia or gonorrhea in the past, a
current urogenital chlamydia infection, a current anal chlamydia or gonorrhea infection, passive anal intercourse in the past six months, and the seven different HPV
genotypes.
AOR= adjusted odds ratio; CI = confidence interval; NI = not included in the multivariable model; NS = not significant in multivariable model.
doi:10.1371/journal.pone.0060696.t003
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correlation structure are slightly higher (with exception of the odds
ratio for HPV Ab in MSW), because these incorporate the small
elevations related to certain HPV types in the log odds ratio
model. Having verified the assumptions underlying an exchange-
able correlation structure, we then compared the associations
between HPV DNA genotypes or HPV Ab genotypes in MSM
and those in women and in MSW. We found that MSM have
similar associations between anal HPV DNA genotypes as women
(Table 3 and 5). Associations between HPV Ab genotypes of MSM
overlap with those of women and MSW when taking the 95%
confidence intervals into account.
Discussion
Positivity rates were high in this young and sexually active
population, without the benefit of HPV vaccination. HPV DNA
positivity and HPV Ab seropositivity were higher in women than
in MSW, with MSM in between, but the association between
detection of type-specific DNA and serum Ab was similar across
gender. The PASSYON study sheds new light on differences in the
natural history of HPV infection between men and women,
indirectly providing evidence for a site-specific natural course of
infection.
In women, HPV DNA positivity rates were lower for each HPV
genotype than HPV Ab seropositivity rates, whereas in MSW,
type-specific HPV DNA positivity rates were higher than HPV Ab
seropositivity rates with the exceptions of HPV Ab-33, -45, and -
58. These specific Ab types had high positivity rates in all genders,
which was confirmed by the results of the GEE analyses.
Significantly higher association between Ab-33 and -45 and
between Ab-33 and -58 was found, meaning that when an
individual is positive for one of these Ab types, he or she is also
frequently found positive for the other type. The gender
differences we observed in HPV DNA positivity and HPV Ab
seropositivity may be related to the type of tissue being infected.
The dry keratinized tissue of the penis is much harder for the virus
to infect than the soft mucosal tissue of the vagina or the anus,
therefore men are less likely than women to develop a humoral
response [8,9,10,11]. Results in MSM support the hypothesis that
Table 4. Adjusted odds ratio and 95% confidence interval for the detection of genital and anal HPV DNA and HPV antibodies
using multilevel analyses (generalized estimating equations [GEE)]) in men who have sex with women only (MSW).
Genital HPV DNA Anal HPV DNA* HPV antibodies
AOR (95% CI) AOR (95% CI) AOR (95% CI)
Age (y)
16–18 Reference Reference
19–21 1.42 (0.67–2.99) 1.99 (0.93–4.27)
22–24 2.02 (0.98–4.19) 2.19 (1.08–4.41)
Number of sex partners, lifetime
1–4 partners Reference NS
5–9 partners 1.39 (0.85–2.29)
$10 partners 2.23 (1.45–3.43)
Condom use steady partner, past 6 months
Inconsistent condom use Reference NS
Consistent condom use 0.33 (0.18–0.60)
No steady partner 0.74 (0.56–0.98)
History of chlamydia or gonorrhea
No Reference NS
Yes 1.49 (1.05–2.12)
Never tested before 0.86 (0.58–1.27)
HPV genotype
HPV16 Reference Reference
HPV18 0.86 (0.62–1.21) 1.10 (0.73–1.66)
HPV31 0.68 (0.47–0.97) 0.41 (0.24–0.71)
HPV33 0.29 (0.19–0.47) 1.27 (0.86–1.86)
HPV45 0.16 (0.09–0.28) 1.44 (0.95–2.18)
HPV52 0.78 (0.55–1.10) 1.14 (0.78–1.66)
HPV58 0.14 (0.08–0.26) 0.77 (0.50–1.17)
Odds of having one HPV genotype when having another HPV genotype within an individual (Alpha)
2.18 (1.46–3.24) 8.73 (5.94–12.83)
The following variables were included into the crude GEE model: age, ethnicity, years sexually active, number of lifetime sex partners, number of sex partners in the last
six months, condom use in the last six months with a steady partner, condom use in the last six months with a casual partner, a chlamydia or gonorrhea in the past, a
current urogenital chlamydia infection, passive anal intercourse in the past six months, and the seven different HPV genotypes.
*The model for anal HPV DNA could not be run for MSW due to small numbers.
AOR= adjusted odds ratio; CI = confidence interval; NI = not included in the multivariable model; NS = not significant in multivariable model.
doi:10.1371/journal.pone.0060696.t004
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Table 5. Adjusted odds ratio and 95% confidence interval for the detection of genital and anal HPV DNA and HPV antibodies
using multilevel analyses (generalized estimating equations [GEE)]) in men who have sex with men (MSM).
Genital HPV DNA* Anal HPV DNA HPV antibodies





0–2 years Reference NS
3–4 years 6.23 (1.51–25.65)
$5 years 7.74 (1.88–31.92)
Number of sex partners, lifetime
1–4 partners NS Reference
5–9 partners 0.95 (0.24–3.78)
$10 partners 2.96 (1.02–8.57)
Condom use casual partner, past 6 months
Inconsistent condom use NS Reference
Consistent condom use 1.10 (0.39–3.10)
No casual partner 5.38 (1.45–20.02)





HPV18 1.00 (0.45–2.20) 0.65 (0.38–1.12)
HPV31 0.68 (0.28–1.64) 0.39 (0.20–0.76)
HPV33 0.19 (0.06–0.65) 0.81 (0.46–1.43)
HPV45 0.19 (0.05–0.71) 0.75 (0.44–1.29)
HPV52 0.53 (0.20–1.40) 0.38 (0.20–0.72)
HPV58 0.13 (0.03–0.58) 0.34 (0.17–0.69)
Odds of having one HPV genotype when having another HPV genotype within an individual (Alpha)
1.79 (0.94–3.43) 8.12 (4.43–14.91)
The following variables were included into the crude GEE model: age, ethnicity, years sexually active, number of lifetime sex partners, number of sex partners in the last
six months, condom use in the last six months with a steady partner, condom use in the last six months with a casual partner, a chlamydia or gonorrhea in the past, a
current urogenital chlamydia infection, a current anal chlamydia or gonorrhea infection, passive anal intercourse in the past six months, and the seven different HPV
genotypes.
*The model for genital HPV DNA could not be run for MSM due to small numbers.
AOR= adjusted odds ratio; CI = confidence interval; NI = not included in the multivariable model; NS = not significant in multivariable model.
doi:10.1371/journal.pone.0060696.t005
Table 6. Association (odds ratio and 95% confidence interval) between genital HPV DNA and HPV-specific antibody genotypes, for
women and MSW.
Women MSW
OR (95% CI) OR (95% CI)
Any pair of homologous HPV DNA and HPV Ab genotypes 2.55 (2.19–2.96) 2.02 (1.28–3.20)
Any pair of HPV DNA genotypes 1.54 (1.35–1.76) 2.07 (1.36–3.15)
Any pair of HPV Ab genotypes 4.14 (3.61–4.76) 9.07 (6.01–13.69)
Any pair of heterologous DNA and Ab genotypes 1.21 (1.09–1.33) 1.01 (0.66–1.53)
Ab = antibody; OR = odds ratio; CI = confidence interval; MSW=men who have sex with women only.
doi:10.1371/journal.pone.0060696.t006
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tissue could play an important role in HPV Ab seropositivity, since
high HPV Ab seropositivity rates in combination with high anal
HPV DNA positivity rates were found in MSM, whereas genital
HPV DNA positivity was low. The ratios between HPV Ab and
anal HPV DNA positivity rates in MSM were similar to the ratios
of HPV Ab and vaginal/anal HPV DNA positivity rates in
women. To examine whether gender-specific factors other than
anatomical site could influence seroconversion, we also compared
the HPV Ab seropositivity rates within women and MSM who
provided both genital and anal samples. Women with only a
genital HPV DNA infection were more often seropositive for the
homologous HPV Ab serotype as compared to MSM with only a
penile HPV DNA infection, whereas HPV Ab seropositivity rates
were comparable for women and MSM with only an anal HPV
DNA infection. These findings support the hypothesis that penile
HPV infections will result less often in seroconversion than vaginal
or anal HPV infections. However, our study was not adequately
powered to detect differences in seropositivity rate between women
and MSM who were infected at one anatomical site only, and we
cannot rule out the possibility that additional factors (e.g. genetic,
behavioural) might contribute to gender-specific differences in
seroconversion. We can only conjecture that anatomical site is a
determinant in the natural course of HPV infection. Obviously, a
cross-sectional design is inherently limited in drawing conclusions
about dynamic associations and it would be worthwhile to further
investigate the relation between site-specific HPV infection and the
humoral immune response in a longitudinal study.
Multivariable GEE analyses helped clarify risk factors for HPV
positivity. One risk factor for a HPV DNA infection in women was
a current chlamydia infection. The site-specific relation between a
chlamydia infection and an HPV infection was noticeable: a
current genital chlamydia infection was associated with genital
HPV DNA positivity and a current anal chlamydia infection with
anal HPV DNA positivity. The underlying mechanism could be
less efficient clearance because of this concurrent infection,
resulting in a persistent infection, or easier invasion into the body.
There were also behavioral factors, such as reported number of
lifetime sex partners, associated with HPV DNA positivity and
HPV Ab seropositivity. These results are in line with previous
studies [11,26,27,28,29,30].
The added value of GEE analyses is the possibility to include all
type-specific HPV DNA and HPV Ab outcomes in one model,
thereby making optimal use of the available data. In addition,
including both HPV DNA and HPV Ab test results in one model
gave us the option to estimate associations between homologous
and heterologous pairs of HPV DNA and HPV Ab genotypes.
Despite the difference in HPV DNA positivity and HPV Ab
seropositivity between women and MSW, no significant gender
difference was seen in the association between a homologous or
heterologous pair of HPV DNA and HPV Ab types. Equal odds
ratios for the associations between HPV DNA positivity and HPV
Ab seropositivity in women and MSW do not imply that the
natural course of the infection would be similar between the sexes.
As shown, women have a higher probability to be seropositive
when HPV DNA positive then MSW. A higher degree of
persistence could be an explanation for the higher seropositivity
in women. Furthermore, a higher association between any two
HPV Ab genotypes in MSW was observed as compared to
women. This higher association in MSW could be due to the less
frequent occurrence of seroconversion. It is conceivable that
characteristics related to seroconversion are restricted to specific
persons such that, on a population level, it will lead to a stronger
clustering of seropositivity in MSW than in women, where
seroconversion is more common.
We also found type-specific HPV DNA and HPV Ab
associations and found some associations between homologous
HPV DNA and HPV Ab types, and between two heterologous
HPV DNA types.
These associations could have occurred because of the high level
of multiple HPV infections. However, the HPV types tested in the
VLP-MIA are phylogenetically related to each other, and belong
to the alpha-7 species (HPV-18, -45) and alpha-9 species (HPV-16,
-31, -33, -52, -58) [31]. Since a high percentage of homology is
found between HPV types of the same species, cross-reactive
HPV-specific antibodies could account for the type-specific
associations.
To summarize, the higher HPV DNA and Ab positivity rates in
women and MSM as compared to heterosexual men, and the
similar HPV DNA and Ab associations across gender suggest a
site-specific natural course of infection. These findings in
combination with the determinants for HPV DNA positivity and
HPV Ab seropositivity can help us interpret the results of future
rounds with more accuracy and will enable us to detect changes in
HPV infection dynamics, both of vaccine and nonvaccine types.
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